Navigation Links
Study on Plasma-Depleted Cord Blood Transplantation Receives Best Abstract Award From The National Marrow Donor Program
Date:11/8/2007

Dr. Auayporn Nademanee of City of Hope leads study showing efficacy of

novel therapy

ARCADIA, Calif. and DUARTE, Calif., Nov. 8 /PRNewswire/ -- The National Marrow Donor Program (NMDP) has selected an abstract written by Dr. Auayporn Nademanee, physician and professor in the Division of Hematology & Hematopoietic Cell Transplantation at City of Hope, and Dr. Robert Chow, Founder and Global Medical Director for StemCyte, as one of four best abstracts at its annual Council Meeting in Minneapolis, MN. The abstract, "Adult Patients with Malignancies Transplanted with Plasma Depleted Cord Blood (PD CB) -- A Retrospective Audited Analysis of 107 Patients" was presented by Dr. Nademanee at the NMDP Council Meeting and has several other co-authors.

The abstract describes the safety and effectiveness of transplanting single or double plasma-depleted umbilical cord blood units into adult patients with cancers of the blood. All of the plasma-depleted cord blood was processed and shipped from the StemCyte International Cord Blood Center in Arcadia, CA. Dr. Nademanee says, "Patients treated with plasma-depleted cord blood demonstrated excellent outcomes in terms of overall survival, transplant-related mortality, and the absence of complications such as graft-versus-host disease. We believe that plasma-depleted cord blood will continue to be an effective treatment for patients with leukemia, lymphoma, and other malignant indications."

Dr. Chow says, "We thank NMDP for selecting ours as one of their Best Abstracts. We are heartened to see the outstanding patient outcomes using StemCyte's plasma-depleted cord blood products. However, none of these results would be possible without the tremendous care given to patients by physicians like Dr. Nademanee at City of Hope. We are gratified to have the support and confidence of physicians at City of Hope and other leading transplant centers around the world." StemCyte has shipped c
'/>"/>

SOURCE StemCyte, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. Penn study finds pro-death proteins required to regulate healthy immune function
2. New study shows promise in reducing surgical risks associated with surgical bleeding
3. Study, meta-analysis examine factors associated with death from heatstroke
4. Study suggests loss of 2 types of neurons -- not just 1 -- triggers Parkinsons symptoms
5. Study says COPD testing is not measuring up
6. Preclinical study suggests organ-transplant drug may aid in lupus fight
7. Ability to cope with stress can increase good cholesterol in older white men, study finds
8. High alcohol consumption increases stroke risk, Tulane study says
9. Mailman School of Public Health study examines link between racial discrimination and substance use
10. Pitt study finds inequality in tobacco advertising
11. Stanford study highlights cost-effective method of lowering heart disease risks

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/29/2009)..., SANTA CRUZ, CA--New connections begin to form b...earn a new task, according to a study published th...versity of California, Santa Cruz, the study invol...s that take place in the brain during motor learni...trained to reach through a slot to get a seed. The...
(Date:11/29/2009)...any doctors unaware the sleep disorder boosts urin...ov. 29 (HealthDay News) -- People who wake up duri...ame a urological problem. Sleep apnea, a breathing...A new study suggests that nighttime urination, or ...r for obstructive sleep apnea, a disorder in which...
(Date:11/28/2009)..., , CHICAGO, Nov. 28 Get...on practice in the clinical routine when Sieme...entific Assembly and Annual Meeting of the Radiolo...r 29 to December 3 at McCormick Place (Booth #825,.... With syngo. via , Siemens, new imaging s...
(Date:11/27/2009)..., , BEDFORD, Mass., Nov. 27 /PRNewswire-Fi...e "Company"), a supplier of precision technology p... that an annual meeting of the Company,s sharehold... The time and location of the meeting will be ann...e Company received a requisition notice from Steph...
(Date:11/27/2009)..., , SAN FRANCISCO, Nov. 27 /PRNewswire-First... announced that Blair Lambert, CFO/COO, will prese...will be held at the May Fair Hotel in London, Engl... GMT. ,, To listen to a live broadcast of The G...et, please log on to www.gymboree.com, click on "O...
Breaking Medicine News(10 mins):Health News:Study shows new brain connections form rapidly during motor learning 2Health News:Study shows new brain connections form rapidly during motor learning 3Health News:Sleep Apnea May Cause Nighttime Urination 2Health News:Sleep Apnea May Cause Nighttime Urination 3Health News:Siemens Boosts Advanced Image Reading Efficiency and Opens New Path Into The Clinical Routine with syngo(R).via 2Health News:Siemens Boosts Advanced Image Reading Efficiency and Opens New Path Into The Clinical Routine with syngo(R).via 3Health News:Siemens Boosts Advanced Image Reading Efficiency and Opens New Path Into The Clinical Routine with syngo(R).via 4Health News:Siemens Boosts Advanced Image Reading Efficiency and Opens New Path Into The Clinical Routine with syngo(R).via 5Health News:GSI Group Calls Shareholders Meeting 2
...Health Minister Dr Anbumani Ramadoss, in an attemp...ese Encephalitis has left for Beijing to approach ...able in a sizeable // quantity. The heavy toll of ...iled discussions with the Chinese minister for Nat...
...Doctors say they want to investigate the case of a...of the virus, reports BBC. // Two Sunday news...in London, was diagnosed as HIV-positive in 2002, ... tests. Stimpson did not take any medication for H...
...Study results showed that people who lived longer ... social position. The research study was carried o...d's School of Public Health who reported their fin...ildren’s with a score more than 130 are considered...
...John Cacioppo and researchers have found that the ...d it runs in to families making it a genetic chara...le should join a group which has more social chara...nd they found that loneliness is not related to he...
...A new study appearing in the November 1, 2005 issu...that a new gene profile may help in predicting how...nd to aggressive chemotherapy. // In many patie...nce of chemotherapy-resistant cancer cells, most p...
...In a breakthrough, which could eventually lead to ...he HIV virus, scientists from the US National Canc...ving in the human body to produce chemicals that b... bacteria. The researchers have successfully...
Other Medicine News:Health News:Indian Government Keen On JE Vaccine Supply And Patenting Of Indian Medicine Formulations 2Health News:British man 'Recovered from HIV' 2Health News:Genetic Profile To Predict Ovarian Cancer Prognosis 2Health News:Genetically modified bacteria to combat HIV 2
(Date:11/27/2009)... ACUO TECHNOLOGIES, developers of h... data migration tools and services, is pleased to ...rk Office has approved a patent application for an...work." Acuo Technologies is pleased to add the U.S.... In general, the granted patent application broad...
(Date:11/25/2009)...5 Heska Corporation ( HS...iagnostic and specialty products to the veterinary...iagnostics Corporation for the supply of blood gas...inary market. ,, (Logo: http://www.newscom...a and Roche share the same passion for innovating ...
(Date:11/25/2009)...wswire/ -- BioTrends Research Group, Inc. released...eport, the first in a multi-phase syndicated marke... Ortho-Biotech,s Stelara, from product launch thro...ve of the report provides quantitative information...ormation from a subset of 20. The reports assess ...
Breaking Medicine Technology:Acuo Technologies Announces Patent for Asset Communication Format Within a Computer Network 2Heska Announces Supply Agreement With Roche Diagnostics 2Heska Announces Supply Agreement With Roche Diagnostics 3Despite Managed Care Obstacles, Interest and Anticipated Use of Centocor Ortho-Biotech's New Psoriasis Agent Stelara (ustekinumab) is High 2FDA Issues Guidance for Derma Sciences Exclusive Wound Dressing With pDADMAC 60241 1FDA Issues Guidance for Derma Sciences Exclusive Wound Dressing With pDADMAC 60241 2FDA Issues Guidance for Derma Sciences Exclusive Wound Dressing With pDADMAC 60241 3FDA Issues Guidance for Derma Sciences Exclusive Wound Dressing With pDADMAC 60241 4Dr Ken Dychtwald to Discuss Looming Caregiver Crunch and the Importance of Proactive Long Term Care Planning 60239 1Dr Ken Dychtwald to Discuss Looming Caregiver Crunch and the Importance of Proactive Long Term Care Planning 60239 2Pittsburgh Partners Launch Promising Family Centered Care Model 3A Special Focus on Promoting Parental Well Being and Healthy Child Development 60237 1Pittsburgh Partners Launch Promising Family Centered Care Model 3A Special Focus on Promoting Parental Well Being and Healthy Child Development 60237 2Pittsburgh Partners Launch Promising Family Centered Care Model 3A Special Focus on Promoting Parental Well Being and Healthy Child Development 60237 3Pittsburgh Partners Launch Promising Family Centered Care Model 3A Special Focus on Promoting Parental Well Being and Healthy Child Development 60237 4Pittsburgh Partners Launch Promising Family Centered Care Model 3A Special Focus on Promoting Parental Well Being and Healthy Child Development 60237 5Pittsburgh Partners Launch Promising Family Centered Care Model 3A Special Focus on Promoting Parental Well Being and Healthy Child Development 60237 6
...y 21 Romark Laboratories, L.C., a,privately-owned...mpletion,of enrollment into its Phase II clinical ...oxanide in combination with standard of care thera...ype 1 who have previously,failed to respond to the...irin). The company expects to announce interim dat...
...rgentina, May 21 Today at the,World Congress of C...w,Perspectives in Atrial Fibrillation Management" ...ogy, St George,s University of London,highlighted ...cal trial,results, as the way forward in the futur...on form of cardiac arrhythmia., To view the Multi...
Other Medicine Technology:Romark Laboratories Completes Enrollment in U.S. Phase II Study of Nitazoxanide for Chronic Hepatitis C Genotype 1 Non-Responders 2Romark Laboratories Completes Enrollment in U.S. Phase II Study of Nitazoxanide for Chronic Hepatitis C Genotype 1 Non-Responders 3ATHENA Clinical Results for Dronedarone (Multaq(R)) Highlighted at the World Cardiology Congress 2ATHENA Clinical Results for Dronedarone (Multaq(R)) Highlighted at the World Cardiology Congress 3ATHENA Clinical Results for Dronedarone (Multaq(R)) Highlighted at the World Cardiology Congress 4ATHENA Clinical Results for Dronedarone (Multaq(R)) Highlighted at the World Cardiology Congress 5ATHENA Clinical Results for Dronedarone (Multaq(R)) Highlighted at the World Cardiology Congress 6
Maumenee tying forceps
Anis tying forceps
McPherson tying forceps
Harms-Tubingen Straight Tying Forceps
Medicine Products: